Related Experiment Video
Updated: Feb 19, 2026
Retzius-Sparing Robot-Assisted Radical Prostatectomy
Published on: May 19, 2022
Robot-assisted Partial Nephrectomy: 5-yr Oncological Outcomes at a Single European Tertiary Cancer Center
Mihai Dorin Vartolomei1, Deliu Victor Matei2, Giuseppe Renne3
1Division of Urology, European Institute of Oncology, Milan, Italy; Department of Cell and Molecular Biology, University of Medicine and Pharmacy, Tirgu Mures, Romania.
Background:
Nowadays, there is a debate about which surgical treatment should be best for clinical T1 renal tumors. If the oncological outcomes are considered, there are many open and laparoscopic series published. As far as robotic series are concerned, only a few of them report 5-yr oncological outcomes.
Objective:
The aim of this study was to analyze robot-assisted partial nephrectomy (RAPN) midterm oncological outcomes achieved in a tertiary robotic reference center.
Design, Setting, And Participants:
Between April 2009 and September 2013, 123 consecutive patients with clinical T1-stage renal masses underwent RAPN in our tertiary cancer center. Inclusion criteria were as follows: pathologically confirmed renal cell carcinomas (RCCs) and follow-up for >12 mo. Eighteen patients were excluded due to follow-up of <12 mo and 15 due to benign final pathology. Median follow-up was 59 mo (interquartile range 44-73 mo). Patients were followed according to guideline recommendations and institutional protocol.
Outcome Measurements And Statistical Analysis:
Outcomes were measured by time to disease progression, overall survival, or time to cancer-specific death. Kaplan-Meier method was used to estimate survival; log-rank tests were applied for pair-wise comparison of survival.
Results And Limitations:
From the 90 patients included, 66 (73.3%) had T1a, 12 (13.3%) T1b, three (3.3%) T2a, and nine (10%) T3a tumors. Predominant histological type was clear cell carcinoma: 67 (74.5%). Fuhrmann grade 1 and 2 was found in 73.3% of all malignant tumors. Two patients (2.2%) had positive surgical margins, and complication rate was 17.8%. Relapse rate was 7.7%, including two cases (2.2%) of local recurrences and five (5.5%) distant metastasis. Five-year disease-free survival was 90.9%, 5-yr cancer-specific survival was 97.5%, and 5-yr overall survival was 95.1%.
Conclusions:
Midterm oncological outcomes after RAPN for localized RCCs (predominantly T1a tumors of low anatomic complexity) were shown to be good, adding significant evidence to support the oncological efficacy and safety of RAPN for the treatment of this type of tumors.
Patient Summary:
Robot-assisted partial nephrectomy seems to be the most promising minimally invasive approach in the treatment of renal masses suitable for organ-sparing surgery as midterm (5 yr) oncological outcomes are excellent.
Insights
Robot-assisted partial nephrectomy (RAPN) shows excellent midterm oncological outcomes for localized renal cell carcinomas. This minimally invasive approach offers a safe and effective organ-sparing option for T1 renal tumors.
Area of Science:
- Urology
- Surgical Oncology
- Minimally Invasive Surgery
Background:
- Debate exists regarding optimal surgical treatment for clinical T1 renal tumors.
- Limited data on 5-year oncological outcomes for robotic partial nephrectomy (RAPN).
Purpose of the Study:
- To analyze midterm oncological outcomes of robot-assisted partial nephrectomy (RAPN).
- Evaluate the efficacy and safety of RAPN in a tertiary robotic reference center.
Main Methods:
- Prospective analysis of 123 patients with clinical T1 renal masses undergoing RAPN.
- Inclusion criteria: confirmed renal cell carcinoma (RCC) and >12 months follow-up.
- Median follow-up of 59 months, with survival analysis using Kaplan-Meier method.
Main Results:
- 90 patients included; predominant tumor type: clear cell carcinoma (74.5%), stage T1a (73.3%).
- Relapse rate: 7.7% (2.2% local, 5.5% distant metastasis).
- Five-year survival rates: disease-free 90.9%, cancer-specific 97.5%, overall 95.1%.
Conclusions:
- RAPN demonstrates good midterm oncological outcomes for localized RCCs, particularly T1a tumors.
- Provides significant evidence supporting the oncological efficacy and safety of RAPN.
- RAPN is a promising minimally invasive approach for organ-sparing surgery of renal masses.
